vs
Amneal Pharmaceuticals, Inc.（AMRX）与RANGE RESOURCES CORP（RRC）财务数据对比。点击上方公司名可切换其他公司
RANGE RESOURCES CORP的季度营收约是Amneal Pharmaceuticals, Inc.的1.1倍（$786.9M vs $722.5M），RANGE RESOURCES CORP净利率更高（22.8% vs 10.8%，领先12.0%），RANGE RESOURCES CORP同比增速更快（18.0% vs 3.9%），过去两年RANGE RESOURCES CORP的营收复合增速更高（14.6% vs 1.5%）
Amneal Pharmaceuticals是一家美国上市制药企业，核心业务涵盖仿制药及专科药物的研发、生产与分销，总部位于新泽西州布里奇沃特，是美国规模最大的仿制药生产商之一。
Range Resources Corporation是一家总部位于美国得克萨斯州沃斯堡的天然气勘探开采企业，核心运营区域为马塞勒斯页岩地层，是该地区拥有土地面积最大的运营商，专注于天然气资源的勘探、开发与生产业务，在北美油气开发领域具备深厚的行业积累。
AMRX vs RRC — 直观对比
营收规模更大
RRC
是对方的1.1倍
$722.5M
营收增速更快
RRC
高出14.1%
3.9%
净利率更高
RRC
高出12.0%
10.8%
两年增速更快
RRC
近两年复合增速
1.5%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $722.5M | $786.9M |
| 净利润 | $78.0M | $179.1M |
| 毛利率 | 44.3% | 94.5% |
| 营业利润率 | — | — |
| 净利率 | 10.8% | 22.8% |
| 营收同比 | 3.9% | 18.0% |
| 净利润同比 | 217.0% | 88.8% |
| 每股收益（稀释后） | $0.19 | $0.75 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMRXRRC
| Q1 26 | $722.5M | — | ||
| Q4 25 | $814.3M | $786.9M | ||
| Q3 25 | $784.5M | $655.3M | ||
| Q2 25 | $724.5M | $699.6M | ||
| Q1 25 | $695.4M | $846.3M | ||
| Q4 24 | $730.5M | $667.0M | ||
| Q3 24 | $702.5M | $567.9M | ||
| Q2 24 | $701.8M | $513.2M |
净利润AMRXRRC
| Q1 26 | $78.0M | — | ||
| Q4 25 | $35.1M | $179.1M | ||
| Q3 25 | $2.4M | $144.3M | ||
| Q2 25 | $22.4M | $237.6M | ||
| Q1 25 | $12.2M | $97.1M | ||
| Q4 24 | $-31.1M | $94.8M | ||
| Q3 24 | $-156.0K | $50.7M | ||
| Q2 24 | $6.0M | $28.7M |
毛利率AMRXRRC
| Q1 26 | 44.3% | — | ||
| Q4 25 | 36.5% | 94.5% | ||
| Q3 25 | 34.9% | 92.5% | ||
| Q2 25 | 39.5% | 95.0% | ||
| Q1 25 | 36.8% | 93.1% | ||
| Q4 24 | 36.0% | 93.7% | ||
| Q3 24 | 38.4% | 94.3% | ||
| Q2 24 | 35.6% | 93.4% |
营业利润率AMRXRRC
| Q1 26 | — | — | ||
| Q4 25 | 13.8% | — | ||
| Q3 25 | 9.0% | — | ||
| Q2 25 | 15.4% | — | ||
| Q1 25 | 14.4% | — | ||
| Q4 24 | 10.4% | — | ||
| Q3 24 | 12.6% | — | ||
| Q2 24 | 13.6% | — |
净利率AMRXRRC
| Q1 26 | 10.8% | — | ||
| Q4 25 | 4.3% | 22.8% | ||
| Q3 25 | 0.3% | 22.0% | ||
| Q2 25 | 3.1% | 34.0% | ||
| Q1 25 | 1.8% | 11.5% | ||
| Q4 24 | -4.3% | 14.2% | ||
| Q3 24 | -0.0% | 8.9% | ||
| Q2 24 | 0.9% | 5.6% |
每股收益（稀释后）AMRXRRC
| Q1 26 | $0.19 | — | ||
| Q4 25 | $0.10 | $0.75 | ||
| Q3 25 | $0.01 | $0.60 | ||
| Q2 25 | $0.07 | $0.99 | ||
| Q1 25 | $0.04 | $0.40 | ||
| Q4 24 | $-0.10 | $0.38 | ||
| Q3 24 | $0.00 | $0.21 | ||
| Q2 24 | $0.02 | $0.12 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $204.0K |
| 总债务越低越好 | — | $1.2B |
| 股东权益账面价值 | — | $4.3B |
| 总资产 | — | $7.4B |
| 负债/权益比越低杠杆越低 | — | 0.28× |
8季度趋势，按日历期对齐
现金及短期投资AMRXRRC
| Q1 26 | — | — | ||
| Q4 25 | $282.0M | $204.0K | ||
| Q3 25 | $201.2M | $175.0K | ||
| Q2 25 | $71.5M | $134.0K | ||
| Q1 25 | $59.2M | $344.6M | ||
| Q4 24 | $110.6M | $304.5M | ||
| Q3 24 | $74.0M | $277.4M | ||
| Q2 24 | $43.8M | $251.1M |
总债务AMRXRRC
| Q1 26 | — | — | ||
| Q4 25 | $2.6B | $1.2B | ||
| Q3 25 | $2.6B | $1.2B | ||
| Q2 25 | $2.2B | $1.2B | ||
| Q1 25 | $2.2B | $1.7B | ||
| Q4 24 | $2.4B | $1.7B | ||
| Q3 24 | $2.4B | $1.7B | ||
| Q2 24 | $2.4B | $1.7B |
股东权益AMRXRRC
| Q1 26 | — | — | ||
| Q4 25 | $-70.8M | $4.3B | ||
| Q3 25 | $-109.5M | $4.2B | ||
| Q2 25 | $-112.1M | $4.1B | ||
| Q1 25 | $-131.7M | $3.9B | ||
| Q4 24 | $-109.3M | $3.9B | ||
| Q3 24 | $-93.4M | $3.9B | ||
| Q2 24 | $-57.5M | $3.9B |
总资产AMRXRRC
| Q1 26 | — | — | ||
| Q4 25 | $3.7B | $7.4B | ||
| Q3 25 | $3.6B | $7.2B | ||
| Q2 25 | $3.4B | $7.1B | ||
| Q1 25 | $3.4B | $7.4B | ||
| Q4 24 | $3.5B | $7.3B | ||
| Q3 24 | $3.5B | $7.2B | ||
| Q2 24 | $3.5B | $7.3B |
负债/权益比AMRXRRC
| Q1 26 | — | — | ||
| Q4 25 | — | 0.28× | ||
| Q3 25 | — | 0.29× | ||
| Q2 25 | — | 0.29× | ||
| Q1 25 | — | 0.43× | ||
| Q4 24 | — | 0.43× | ||
| Q3 24 | — | 0.44× | ||
| Q2 24 | — | 0.44× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $257.5M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | 1.44× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流AMRXRRC
| Q1 26 | — | — | ||
| Q4 25 | $130.3M | $257.5M | ||
| Q3 25 | $118.5M | $247.5M | ||
| Q2 25 | $83.8M | $336.2M | ||
| Q1 25 | $7.4M | $330.1M | ||
| Q4 24 | $118.1M | $217.9M | ||
| Q3 24 | $141.8M | $245.9M | ||
| Q2 24 | $39.7M | $148.8M |
自由现金流AMRXRRC
| Q1 26 | — | — | ||
| Q4 25 | $108.5M | — | ||
| Q3 25 | $106.2M | — | ||
| Q2 25 | $61.0M | — | ||
| Q1 25 | $-5.8M | — | ||
| Q4 24 | $102.9M | — | ||
| Q3 24 | $124.8M | — | ||
| Q2 24 | $29.0M | — |
自由现金流率AMRXRRC
| Q1 26 | — | — | ||
| Q4 25 | 13.3% | — | ||
| Q3 25 | 13.5% | — | ||
| Q2 25 | 8.4% | — | ||
| Q1 25 | -0.8% | — | ||
| Q4 24 | 14.1% | — | ||
| Q3 24 | 17.8% | — | ||
| Q2 24 | 4.1% | — |
资本支出强度AMRXRRC
| Q1 26 | — | — | ||
| Q4 25 | 2.7% | — | ||
| Q3 25 | 1.6% | — | ||
| Q2 25 | 3.2% | — | ||
| Q1 25 | 1.9% | — | ||
| Q4 24 | 2.1% | — | ||
| Q3 24 | 2.4% | — | ||
| Q2 24 | 1.5% | — |
现金转化率AMRXRRC
| Q1 26 | — | — | ||
| Q4 25 | 3.72× | 1.44× | ||
| Q3 25 | 50.00× | 1.72× | ||
| Q2 25 | 3.74× | 1.42× | ||
| Q1 25 | 0.61× | 3.40× | ||
| Q4 24 | — | 2.30× | ||
| Q3 24 | — | 4.85× | ||
| Q2 24 | 6.62× | 5.18× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMRX
| Affordable Medicines net | $423.0M | 59% |
| AvKARE net | $166.0M | 23% |
| Specialty net | $133.0M | 18% |
RRC
| Natural Gas Natural Gas Liquids And Oil Sales | $745.5M | 95% |
| Brokered Natural Gas And Marketing | $41.3M | 5% |
